timothy sykes logo

Stock News

Exact Sciences Stock Skyrockets: Unraveling The Surge

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Bryce Tuohey Fact-checked by Matt Monaco
Updated 11/20/2025, 9:19 am ET 11/20/2025, 9:19 am ET | 6 min 6 min read
Exact Sciences Stock Skyrockets: Unraveling The Surge Thumbnail

Exact Sciences Corporation stocks have been trading up by 17.93 percent following promising clinical trial results and FDA approval.

Candlestick Chart

Live Update At 09:19:02 EST: On Thursday, November 20, 2025 Exact Sciences Corporation stock [NASDAQ: EXAS] is trending up by 17.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Overview of Recent Financial Metrics

Let’s delve into Exact Sciences’ recent performance, where figures speak volumes. The company’s third-quarter revenue stands at approximately $850.74M, indicating consistent market demand for its innovative screening solutions. A deep dive into Exact Sciences’ profitability reveals a challenging scenario with negative profitability margins. For instance, their EBIT margin stands at -33.7%, reminding us of the uphill battles startups face to balance cutting-edge advancements with fiscal prudence. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This highlights that despite generating substantial revenue, maintaining profitability is crucial for the company’s longevity in the competitive landscape.

The company’s gross margin paints a brighter picture, marked at 68.2%, which is notably commendable and points toward efficient production practices and strong pricing strategies. Cash flow from ongoing operations climbed to about $219.92M, an impressive increase that emphasizes the underlying robust business operations and cash generation capability. However, the period-ending cash reserves clocked in at $182.44M, slightly underscoring the liquidity focus amidst operational expansion.

Certain complexities also emerge from the debt perspective: with a total debt-to-equity ratio of 1.02, Exact Sciences presents a picture of a relatively leveraged financial profile, demanding active debt management strategies. With receivable and invoice turnovers standing at 9.5 and 6.3 respectively, the company efficiently channels its assets towards generating swift revenue inflows. Despite setbacks reflected by negative profitability, Exact Sciences’ short-term financial soundness is reflected in its current ratio of 2.9 and a quick ratio of 2.3.

Recent share price data echoes this journey of highs and lows. On Nov 19, 2025, the stock opened at $69.5, reaching an intraday high of $89.67 before settling down at $86.18 at market close. These swing indicate active trading behavior influenced heavily by possible acquisition talks and market speculative behavior during the day’s session. In conclusion, Exact Sciences has portrayed a strong base of revenue growth yet must align its profitability strategies to sustain impactful growth in the competitive arena of medical tech innovations.

The Market Impact: Acquisition and Innovation

The speculation of a takeover by Abbott Laboratories cannot be ignored as a focal point in recent market activities. Reports reveal that Abbott is closing in on finalizing this significant acquisition, and the market seems more than curious. The speculation resulted in a stock surge not just in price but also in curiosity, suggesting investors are hopeful about this union.

Analyst projections reinforce this momentum. A takeover quote exceeding $100 a share would mean an astounding valuation boost, propelling Exact Sciences into an elite financial realm, attracting more public and institutional investors. Existing stockholders watch closely, given that any acquisition news often marks a turning point in their financial investments.

The second wave of buzz comes from the ALTUS study, whose success lays a platform for healthcare transformation as well as revenue expansion. Early liver cancer detection offers multiple possibilities, both socio-healthly and commercially. This revelation in the medical field may pave Exact Sciences’ path towards instant credibility and categorical leadership, asserting dominance over industry norms. Meanwhile, the partnership with Freenome keeps the pipeline of innovative cancer screening tests streamlining future growth. Nevertheless, securing FDA approval for these blood-based tests remains crucial for these strategic expansions to prove profitable.

More Breaking News

Conclusion: Looking Ahead for EXAS

As Exact Sciences steps towards potential acquisition and enhances cancer diagnostics, the financial community closely observes to see if its endeavors continue to bolster trader confidence. For potential and current traders, such strides signal two implicit questions – whether these strategic alignments justify current valuations and what the plausible timelines for tangible returns could be. As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This mindset is pivotal for those navigating Exact Sciences’ trajectory.

Lastly, the narrative surrounding critical innovations in healthcare products continuously fuels optimism and advancements. These developments come with underlying risks but also an array of unparalleled opportunities. As Exact Sciences navigates this evolving landscape, perseverance in operational efficiency combined with leveraging strategic partnerships can chart paths to reward potential stakeholders and secure a path of visionary leadership in healthcare innovation.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”